Prostate Cancer International is a
non-profit for 2012 as rated by Great NonProfits
A new paper recently published on line in Urology (“the Gold Journal”) suggests that men with diabetes who are treated with curative intent for localized prostate cancer using external beam radiation therapy may experience higher than normal risk for late genitourinary complications and adverse effects. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: diabetes, external beam, localized, radiation | Leave a Comment »
A recently reported study by a group of German researchers has indicated that [11C]choline PET/CT scanning is not sufficently accurate to be able to identify, localize, and target areas of cancerous tissue within the prostate of a man known to have prostate cancer. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: C-11, choline, localized, PET/CT, scan | 1 Comment »
Since 1977 a group of Swedish researchers has followed a prospectively evaluated, population-based cohort of 223 consecutive patients, all diagnosed clinically with localized prostate cancer, who received no treatment other than observation (“watchful waiting”) until symptomatic progression and androgen deprivation therapy (ADT) became necessary. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: localized, Sweden, waiting, watchful | 12 Comments »
We understand from media reports that the French medical device company EDAP TMS has submitted documentation to the U.S. Food & Drug Administration (FDA) for pre-market approval of their Ablatherm technology for treatment of low-risk, localized prostate cancer with high-intensity, focused ultrasound (HIFU). … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: Ablatherm, focused, HIFU, high-intensity, localized, ultrasound | 4 Comments »
An article in this week’s New England Journal of Medicine offers us 15-year functional outcomes data from the Prostate Cancer Outcomes Study (PCOS), which enrolled 3,533 men in whom prostate cancer was diagnosed in 1994 or 1995. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: localized, outcomes, radiation, surgery, therapy | 3 Comments »
A new article from the clinical research group at The Cleveland Clinic has suggested that men > 70 years of age are at significantly higher risk for recurrence of their prostate cancer if treated by radical prostatectomy than younger men with comparable diagnostic criteria. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: age, localized, outcome, radical prostatectomy, risk | 2 Comments »
According to a news item on the web site of the University of California, San Francisco, a new paper from a team lead by a UCSF researcher is, “The most comprehensive retrospective study ever conducted comparing how the major types of prostate cancer treatments stack up to each other in terms of saving lives and cost effectiveness.” … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: cost, effectiveness, localized, Treatment | 4 Comments »
Data reported by Meier et al. and presented at the recent annual meeting of the American Society for Radiation Oncology (ASTRO) provide some early guidance on the efficacy and safety of sterotactic body radiation therapy (SBRT) in treatment of men with intermediate-risk, localized prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: body, CyberKnife, intermediate risk, localized, radiation, SBRT, stereotactic | Leave a Comment »
According to data to be presented this afternoon at the annual meeting of the American Society for Radiation Oncology (ASTRO), a double-blind, randomized, placebo-controlled clinical trial has shown that sildenafil citrate can be used to improve sexual function of prostate cancer patients treated with radiation therapy. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: function, localized, radiation, sexual, sildenafil, therapy | Leave a Comment »
A new paper in the Journal of Oncology Practice has attempted to compare the cost-effectiveness of stereotactic body radiation therapy (SBRT) to that of intensity-modulated radiation therapy (IMRT) in the treatment of men with low- to intermediate-risk prostate cancer. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: cost, efficacy, IMRT, intermediate risk, localized, low risk, outcome, SBRT | 3 Comments »
It is sometimes very irritating that good and thoughtful articles appearing in the professional journals are not easily accessible to a wider lay readership. An editorial by Behfar Ehdaie, MD, in the September issue of the Journal of Urology offers a case in point. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: Diagnosis, expectant, localized, Management, Treatment | Leave a Comment »
Nymox Pharmaceutical Corp. has announced the initiation of patient enrollment for a Phase II trial of NX-1207 for the treatment of men with low-risk, localized prostate cancer. This product is already in Phase III clinical trials in Europe and the USA for the treatment of men with benign prostatic hyperplasia (BPH). … READ MORE …
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment | Tagged: localized, low risk, NX-1207, trial | 3 Comments »
The April issue of AUA News (a magazine only available to AUA members) includes an interesting article by David Penson, MD, in which he previews a lecture he will be giving at the upcoming annual meeting of the American Urological Association (in Atlanta, later this month). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: baseline, database, localized, outcone, regitry, standardized, trial | 6 Comments »
In February we reported on a presentation by Sheets et al. at the Genitourinary Cancer Symposium. The presentation addressed the comparative effectiveness and safety of 3D conformal, intensity-modulated, and proton beam forms of radiation therapy (3D-CRT, IMRT, and PBRT, respectively). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: 3D-CRT, comparative, effectiveness, IMRT, localized, outcome, PBRT, radiation | 3 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site